ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany. It operates through Commercial & Wholesale and Digital Assets segments. The company distributes a range of pharmaceutical goods and medical products to treat various health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. It also operates as a decentralized AI treasury company that invests in the future of AI infrastructure through strategic ownership of 0G tokens. In addition, the company invests in early-stage companies. The company was formerly known as Flora Growth Corp. and changed its name to ZeroStack Corp. in January 2026. ZeroStack Corp. was incorporated in 2019 and is based in Toronto, Canada.…
Zerostack’s Crypto Holdings Top $1 Billion
ZeroStack (NASDAQ: ZSTK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Asset Management industry, part of the Financial Services sector, and reports about 21 employees.
The shares were at 2.800 USD on 20 November 2026, down 67.1% over 52 weeks. Its 52-week range is 1.320 USD to 15.04 USD: the price is 81.4% below the high and 112.1% above the low.
Its market capitalisation is 61.03M USD.
ZeroStack reports return on equity of -169.7%, an operating margin of -31.9% and revenue up 40.7% year over year.
Its debt exceeds its cash by 117.00K USD, a debt-to-equity ratio of 0.76. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 11.00 USD is 292.9% above the current price.